[Alveolo-interstitial pneumonia due to Temozolamide]

Rev Mal Respir. 2008 Sep;25(7):880-4. doi: 10.1016/s0761-8425(08)74357-2.
[Article in French]


Introduction: Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy.

Case report: We report the case of a 56 year old woman presenting with alveolo-interstitial pneumonia after treatment with Temozolomide. Initially she received induction treatment with Temozolomide and concomitant radiotherapy for bifocal high grade glioblastoma. A month later she received, as scheduled, the first course of Temozolomide maintenance chemotherapy. Grade II dyspnoea developed a few days later. High resolution computed tomography showed alveolo-interstitial opacities with basal predominance, associated with alveolar nodules. Broncho-alveolar lavage showed a lymphocytosis. No bacteria were isolated from microbiological samples. A final diagnosis of drug-induced pneumonia was based on the time sequence and absence of other causes.

Conclusion: There is little literature concerning the pulmonary toxicity of Temozolomide. However, our case report of drug-induced pneumonia and similar observations in the databases of regional pharmacovigilance centres suggest that this side effect should be included in the summary of product characteristics.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Alkylating / adverse effects*
  • Brain Neoplasms / drug therapy
  • Bronchoalveolar Lavage
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Female
  • Glioblastoma / drug therapy
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / diagnostic imaging
  • Lymphocytosis
  • Middle Aged
  • Radiography, Thoracic
  • Temozolomide
  • Time Factors
  • Tomography, X-Ray Computed


  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide